^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Clostridium novyi-NT

    i
    Other names: Clostridium novyi-NT, BVD-CNV, BVD-CNV/IT, BVD-CNV/IV, C.novyi-NT, Clostridium novyi-NT spores, Clostridium-novyi-non-toxic, CNV-NT, BVD-550
    Associations

    News

    Trials
    Company:
    BioMed Valley Discoveries
    Drug class:
    Cell death stimulant
    Related drugs:
    Associations

    News

    Trials
    23d
    Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Clostridium novyi-NT
    2years
    Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov)
    P1, N=18, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2021 --> Oct 2024 | Trial primary completion date: Oct 2021 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Clostridium novyi-NT
    over4years
    Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov)
    P1, N=18, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Oct 2020 --> Oct 2021
    Clinical • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Clostridium novyi-NT